ArticleAnnals of surgical oncology2024
Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy.
Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review.Annals of surgical oncology · 2025Pooled it
- Evolution of Axillary Surgical Management of Patients with Occult Breast Cancer with Axillary Metastasis.Annals of surgical oncology · 2026Article
- Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy.Annals of surgical oncology · 2026Observational
- DEGRO practical guidelines: radiotherapy of breast cancer-Regional nodal irradiation.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis following Neoadjuvant Therapy in Patients with Clinically Node-Negative, Hormone Receptor-Positive, HER2-Negative Breast Cancer.Annals of surgical oncology · 2026Observational
- Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.Annals of surgical oncology · 2026Article
- Iodine seed-marking protocol for response-guided axillary de-escalation after neoadjuvant therapy in node-positive breast cancer.Translational cancer research · 2026Article
- Correlation between the drainage time in dynamic indocyanine green lymphography (ICG) and axillary lymph nodes metastatic involvement in breast cancer patients-a prospective study.Breast cancer research and treatment · 2026Article
- The role of regional nodal irradiation in clinically node-positive breast cancer patients who undergo neoadjuvant chemotherapy and breast-conserving surgery.Breast cancer research and treatment · 2026Article
- Role of Sentinel Lymph Node Biopsy with Blue Dye Only after Neoadjuvant Systemic Treatment in Patients with Breast Cancer Who Had Biopsy-Proven Node-Positive Disease at Admission: SENATURK-ROSANNA Study.Breast care (Basel, Switzerland) · 2026Article
- Locoregional Considerations for Invasive Lobular Carcinoma.Current breast cancer reports · 2026Review
- Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.The Lancet. Oncology · 2026Article
- De-escalating the axilla: oncologic and morbidity outcomes of targeted axillary dissection versus axillary lymph node dissection following neoadjuvant systemic therapy in clinically node-positive breast cancer within a single institution.Frontiers in oncology · 2026Article
- Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1-2 Breast Cancer: An Internally Validated PET/CT-Integrated Nomogram.Current oncology (Toronto, Ont.) · 2025Article
- ASO Author Reflections: Equity in the Surgical Management of the Axilla.Annals of surgical oncology · 2025Article
- Breast Cancer Surgery at a Tertiary Center in Greece: Clinicopathological Associations and Patient Outcomes.Cureus · 2025Article
- Real-World Assessment of Locoregional Management of the Axilla in Node-Positive Breast Cancer After Neoadjuvant Chemotherapy.Annals of surgical oncology · 2025Article
- Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.Annals of surgical oncology · 2025Observational
- Axillary lymph node metastasis in breast cancer: from historical axillary surgery to updated advances in the preoperative diagnosis and axillary management.BMC surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAxillary management after neoadjuvant chemotherapy (NAC) is evolving but axillary lymph node dissection (ALND) remains the standard of care for patients with residual nodal disease. The results of the Alliance A011202 trial evaluating the oncologic safety of ALND omission in this cohort are pending but we hypothesize that ALND omission is already increasing.
methodsThe National Cancer Database was queried to identify patients diagnosed with cT1-3N1M0 breast cancer who underwent NAC and had residual nodal disease (ypN1mi-2) from 2012 to 2021. Temporal trends in omission of completion ALND were assessed annually. Multivariable logistic and Cox regression models were used to identify factors associated with ALND omission and overall survival (OS), respectively.
resultsA total of 6101 patients were included; the majority presented with cT2 disease (57%), with 69% HER2+, 23% triple-negative, and 8% hormone receptor-positive/HER2-. Overall, 34% underwent sentinel lymph node biopsy (SLNB) alone. Rates of ALND were the lowest in the last 4 years of observation. After adjustment, treatment at community centers (vs. academic) and lower pathologic nodal burden were associated with omission of ALND. ALND omission was associated with a higher unadjusted OS (5-year OS: 86% SLNB alone vs. 84% ALND; log-rank p = 0.03), however this association was not maintained after adjustment.
conclusionsDespite the impending release of the Alliance A011202 results, omission of ALND in patients with residual nodal disease after NAC is increasing. This practice appears more prominent in community centers and in patients with a lower burden of residual nodal disease. No association with OS was noted.
Indexed as
Identifiers
39230856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.